Mitsubishi Tanabe Pharma Corp (4508):企業の財務・戦略的SWOT分析

◆英語タイトル:Mitsubishi Tanabe Pharma Corp (4508) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C4820
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Mitsubishi Tanabe Pharma Corp (4508) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes, kidney diseases, central nervous system (CNS) disorders and others. It also develops vaccines for preventing various infectious diseases. Mitsubishi Tanabe’s major brands include remicade, simponi, tenelia, ceredist, lexapro, flucort f, nanpao, alegysal bien and okinazole. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It has subsidiaries in Asia, Europe and North America. Mitsubishi Tanabe is headquartered in Chuo-ku, Osaka, Japan.

Mitsubishi Tanabe Pharma Corp Key Recent Developments

Jul 02,2018: Mitsubishi Tanabe Pharma and Osaka University co-found the Department of Neuro-Medical Science – Toward the Innovative Drug Discovery for refractory Neurological Diseases
Jul 02,2018: Mitsubishi Tanabe Pharma and Osaka University co-found the “Department of Neuro-Medical Science”
Jul 02,2018: Mitsubishi Tanabe Pharma: Open Call for Applicants for investigator-Initiated Clinical Research Funds
May 30,2018: Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development
May 30,2018: Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Mitsubishi Tanabe Pharma Corp – Key Facts 6
Mitsubishi Tanabe Pharma Corp – Key Employees 7
Mitsubishi Tanabe Pharma Corp – Key Employee Biographies 8
Mitsubishi Tanabe Pharma Corp – Major Products and Services 9
Mitsubishi Tanabe Pharma Corp – History 11
Mitsubishi Tanabe Pharma Corp – Company Statement 18
Mitsubishi Tanabe Pharma Corp – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Joint Venture 22
Section 2 – Company Analysis 23
Company Overview 23
Mitsubishi Tanabe Pharma Corp – Business Description 24
Product Category: Ethical Drugs 24
Performance 24
Product Category: OTC Products 24
Performance 24
Product Category: Others 24
Performance 24
Product Category: Royalty Revenue 25
Performance 25
Geographical Segment: Asia 25
Performance 25
Geographical Segment: Europe 25
Performance 25
Geographical Segment: Japan 25
Performance 25
Geographical Segment: North America 25
Performance 25
Geographical Segment: Others 25
Performance 25
R&D Overview 25
Mitsubishi Tanabe Pharma Corp – Corporate Strategy 26
Mitsubishi Tanabe Pharma Corp – SWOT Analysis 27
SWOT Analysis – Overview 27
Mitsubishi Tanabe Pharma Corp – Strengths 27
Mitsubishi Tanabe Pharma Corp – Weaknesses 28
Mitsubishi Tanabe Pharma Corp – Opportunities 29
Mitsubishi Tanabe Pharma Corp – Threats 30
Mitsubishi Tanabe Pharma Corp – Key Competitors 31
Section 3 – Company Financial Ratios 32
Financial Ratios – Capital Market Ratios 32
Financial Ratios – Annual Ratios 33
Performance Chart 36
Financial Performance 36
Financial Ratios – Interim Ratios 37
Financial Ratios – Ratio Charts 38
Section 4 – Company’s Lifesciences Financial Deals and Alliances 39
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 39
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 40
Mitsubishi Tanabe Pharma Corp, Recent Deals Summary 41
Section 5 – Company’s Recent Developments 42
Jul 02, 2018: Mitsubishi Tanabe Pharma and Osaka University co-found the Department of Neuro-Medical Science – Toward the Innovative Drug Discovery for refractory Neurological Diseases 42
Jul 02, 2018: Mitsubishi Tanabe Pharma and Osaka University co-found the “Department of Neuro-Medical Science” 43
Jul 02, 2018: Mitsubishi Tanabe Pharma: Open Call for Applicants for investigator-Initiated Clinical Research Funds 44
May 30, 2018: Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development 45
May 30, 2018: Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development 46
Mar 26, 2018: Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology to Begin Collaborative Creation for Improving Efficiency of Clinical Trials for New Drug Development 47
Dec 13, 2017: Strategic Collaboration for the Development of the Antibody Drug to Treat Neurodegenerative Diseases including ALS 48
Nov 01, 2017: Mitsubishi Tanabe Pharma: Financial Results for the First Six Months of the Fiscal year ending March 31, 2018 49
Oct 11, 2017: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct “JOINUS,” a New Drug Discovery Program Using Drug-Repositioning Compound Library 51
Sep 29, 2017: MT Pharma: Organizational Change and Personnel Change 52
Section 6 – Appendix 53
Methodology 53
Ratio Definitions 53
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Mitsubishi Tanabe Pharma Corp, Key Facts 6
Mitsubishi Tanabe Pharma Corp, Key Employees 7
Mitsubishi Tanabe Pharma Corp, Key Employee Biographies 8
Mitsubishi Tanabe Pharma Corp, Major Products and Services 9
Mitsubishi Tanabe Pharma Corp, History 11
Mitsubishi Tanabe Pharma Corp, Other Locations 19
Mitsubishi Tanabe Pharma Corp, Subsidiaries 20
Mitsubishi Tanabe Pharma Corp, Joint Venture 22
Mitsubishi Tanabe Pharma Corp, Key Competitors 31
Mitsubishi Tanabe Pharma Corp, Ratios based on current share price 32
Mitsubishi Tanabe Pharma Corp, Annual Ratios 33
Mitsubishi Tanabe Pharma Corp, Annual Ratios (Cont...1) 34
Mitsubishi Tanabe Pharma Corp, Annual Ratios (Cont...2) 35
Mitsubishi Tanabe Pharma Corp, Interim Ratios 37
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 39
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 40
Mitsubishi Tanabe Pharma Corp, Recent Deals Summary 41
Currency Codes 53
Capital Market Ratios 53
Equity Ratios 54
Profitability Ratios 54
Cost Ratios 55
Liquidity Ratios 55
Leverage Ratios 56
Efficiency Ratios 56

List of Figures
Mitsubishi Tanabe Pharma Corp, Performance Chart (2014 - 2018) 36
Mitsubishi Tanabe Pharma Corp, Ratio Charts 38
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 39
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 40

★海外企業調査レポート[Mitsubishi Tanabe Pharma Corp (4508):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Numab Innovation AG-製薬・医療分野:企業M&A・提携分析
    Summary Numab Innovation AG (Numab) designs and develops novel therapeutics for the treatment of severe diseases. The company’s lead program ND007, a bispecific antibody fragment which is being evaluated for the treatment of autoimmune diseases. Numab’s other pipeline drug candidates include ND009, …
  • Murree Brewery Co. Ltd.:企業の戦略・SWOT・財務情報
    Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Moberg Pharma AB (MOB):製薬・医療:M&Aディール及び事業提携情報
    Summary Moberg Pharma AB (Moberg Pharma), formerly Moberg Derma AB, is a pharmaceutical company. The company provides commercializes proprietary, acquired and licensed products. It provides treatment of skin diseases. Moberg Pharma treats fungal infection or psoriasis, discolored and fungus-damaged …
  • Linde AG (LIN):製薬・医療:M&Aディール及び事業提携情報
    Summary Linde AG (Linde) is a provider of industrial gases and engineering services. The company specializes in the planning, procurement, construction and operation of gas production and processing plants. It offers a wide range of compressed, liquefied gases and chemicals. It also offers engineeri …
  • KLA-Tencor Corporation (KLAC):企業の財務・戦略的SWOT分析
    KLA-Tencor Corporation (KLAC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • OriGene Technologies Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary OriGene Technologies Inc (OriGene) is a research tool company that develops cDNA. The company creates commercial collection of full-length human cDNAs in expression vector. It develops, manufactures and markets genome research and diagnostic products. OriGene provides products such as qPCR r …
  • Koc Holding AS:企業の戦略・SWOT・財務分析
    Koc Holding AS - Strategy, SWOT and Corporate Finance Report Summary Koc Holding AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Zeta Petroleum Plc (ZTA):石油・ガス:M&Aディール及び事業提携情報
    Summary Zeta Petroleum Plc (Zeta) is an oil and gas exploration and production company. The company explores, develops and produces natural gas and crude oil. It owns and operates oil and gas assets such as Bobocu Gas Field, Suceava Concession, Jimbolia Oil Field, and Grivita Nord Oil Field. Zeta’s …
  • TEGNA Inc (TGNA):企業の財務・戦略的SWOT分析
    TEGNA Inc (TGNA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Mercury Systems, Inc.:企業のM&A・事業提携・投資動向
    Mercury Systems, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mercury Systems, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Transport for London:企業の戦略的SWOT分析
    Transport for London - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Norsk Hydro ASA (NHY)-エネルギー分野:企業M&A・提携分析
    Summary Norsk Hydro ASA (Hydro) is a global supplier of aluminum and an electricity producer. Its operations span the value chain, from bauxite extraction to the production of rolled and extruded aluminum products and building systems. Its portfolio of products include bauxite, alumina, extrusion in …
  • Qatar Electricity & Water Co QPSC:企業の発電所・SWOT分析2018
    Qatar Electricity & Water Co QPSC - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Helmerich & Payne Inc (HP):企業の財務・戦略的SWOT分析
    Helmerich & Payne Inc (HP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Singapore Telecommunications Ltd:企業の戦略・SWOT・財務情報
    Singapore Telecommunications Ltd - Strategy, SWOT and Corporate Finance Report Summary Singapore Telecommunications Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Nabriva Therapeutics Plc (NBRV):製薬・医療:M&Aディール及び事業提携情報
    Summary Nabriva Therapeutics Plc (Nabriva) is a biopharmaceutical company that researches and develops antibiotics for the treatment of infections. The company’s product candidate includes lefamulin, a pleuromutilin antibiotic, being developed in both intravenous and oral formulations for the treatm …
  • Tilaknagar Industries Ltd:企業の戦略・SWOT・財務分析
    Tilaknagar Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Tilaknagar Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • CIRCOR Aerospace Products Group:企業の戦略・SWOT・財務分析
    CIRCOR Aerospace Products Group - Strategy, SWOT and Corporate Finance Report Summary CIRCOR Aerospace Products Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Stealth BioTherapeutics Corp (MITO):企業の戦略的SWOT分析
    Stealth BioTherapeutics Corp (MITO) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Fluor Corporation (FLR):企業の財務・戦略的SWOT分析
    Fluor Corporation (FLR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆